William Oh: For men with aggressive prostate cancer, genetic testing can inform treatment decisions.

Quoting William Oh, Chief Medical Officer of Prostate Cancer Foundation, on LinkedIn:

”Germline exome sequencing of over 17k men of European ancestry with aggressive and non-aggressive prostate cancer showed an association between the known genes BRCA2, ATM, and NBN with aggressive prostate cancer, in addition to evidence of a link to rare variants in MSH2, XRCC2, and MRE11A. For men with aggressive prostate cancer, genetic testing can inform treatment decisions. We need similar datasets in non-European populations.”

For the article click here.
Source: William Oh/LinkedIn